NOVEL ANTITUMOR AGENT AND METHOD FOR SCREENING SAME

• 特願2012-015982 (2012.1.27) JP

The present invention provides a novel antitumor agent with a novel action mechanism. The novel antitumor agent comprises, as the active ingredient, a substance capable of inhibiting a cell cycle-dependent Rho GTPase activating protein (RhoGAP). The RhoGAP, which depends on the cell cycle, plays an important role in the course of the acquisition of metastatic ability and/or invasive ability by cancer cells. By targeting the RhoGAP, the invasion and/or metastasis of cancer cells can be controlled. As the substance capable of inhibiting the cell cycle-dependent RhoGAP, an antisense oligonucleotide against an RhoGAP-encoding gene, an oligonucleotide inducing RNA interference, etc. can be cited. An oligonucleotide containing a synthetic nucleic acid such as BNA is preferred because of the high stability thereof. The present invention also provides a screening method for selecting an antitumor agent which is capable of suppressing the invasion and/or metastasis of cancer cells by a novel mechanism. This method for screening a novel antitumor agent is characterized in that a substance capable of inhibiting a cell cycle-dependent Rho GTPase activating protein is selected thereby.

• OSAKA UNIVERSITY

• ISHII, MASARU,
• KAGAWA, YOSHINORI,
• MORI, MASAKI,
• ISHII, HIDESHI

• A61K  45/00      Ａ６１Ｋ３１／００～Ａ６１Ｋ４１／００に属さない活性成分を含有する医薬品製剤
• A61K  31/7088    ３個以上のヌクレオシドまたはヌクレオチドを持つ化合物
• A61K  31/711     天然のデオキシリボ核酸，すなわちアデニン，グアニン，シトシン又はチミンに結合した２’－デオキシリボースのみを含み，３’－５’ホスホジエステル結合を持つもの
• A61K  48/00      遺伝子疾病を治療するために生体の細胞内に挿入する遺伝子物質を含有する医療用製剤；遺伝子治療
• A61P  35/00      抗腫瘍剤
• C12N  15/113     遺伝子の発現を調節する非コード核酸、例．アンチセンスオリゴヌクレオチド
• C12Q   1/68      核酸を含むもの
• G01N  33/15      医薬
• G01N  33/50      生物学的材料，例．血液，尿，の化学分析；生物学的特異性を有する配位子結合方法を含む試験；免疫学的試験
• G01N  33/574     癌のためのもの